Orexo (OTCQX:ORXOF, NASDAQ OMX:ORX) AB US President Robert DeLuca joined Steve Darling from Proactive to discuss the company’s pivotal efforts in addressing the opioid epidemic and the launch of innovative treatment solutions. Originally a Swedish formulation firm, Orexo has evolved into a global leader in opioid use disorder therapies, underpinned by 11 years of unwavering commitment to this pressing issue. DeLuca highlighted the success of Orexo’s flagship product, Zubsolv, a sublingual medication for opioid dependency, which has positively impacted countless lives.
He also discussed the company’s latest innovation, OX124, a high-dose naloxone product designed to counteract life-threatening opioid overdoses, especially those caused by illicit fentanyl, a substance implicated in 80% of opioid overdose deaths in the U.S. Looking ahead, Orexo is poised for major milestones in 2024, including filing for FDA approval of OX124 and launching a nasal powder epinephrine product as a more accessible alternative to traditional epinephrine auto-injectors like EpiPen.
Orexo's amorphOX platform, a proprietary drug formulation technology, continues to drive advancements in stable and effective drug delivery, ensuring patients receive life-saving treatments precisely when needed. DeLuca remarked, “We’ve got a lot of work to do as a company, as an industry, and as a country to get ahead of this disease,” while praising the collaborative efforts of Orexo’s teams in the U.S. and Sweden for their role in these advancements. With a steadfast focus on combating the opioid crisis and addressing other critical medical needs, Orexo is leading the way in providing hope and solutions for those affected by substance use disorders.